Stock To Watch: Jazz Pharmaceuticals plc (NASDAQ:JAZZ)


The leading market experts have placed a mean price target of $186.20 on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stock. This price level, which is estimated to be attained in one-year, indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $2.71 a share for the upcoming quarter and $10.07 for the current fiscal.

Technical View

The technical analysis of Jazz Pharmaceuticals plc plainly substantiates that the 50-day moving average of Jazz Pharmaceuticals plc is $142.86, and stock is trading $-6.30 points away or -4.41% from its 50-day moving average of $142.86. Further it is trading $-2.03 or -1.47% away its 200-day moving average of $138.59. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) 52-week high is $188.24 and the 52-week low is $108.50.

This explains if the stock moves $-51.68, it will post a 52-week high. In event of +25.86% decline, a 52-week low will be hit.

Taking the valuation aspect to emphasize the valuation of Jazz Pharmaceuticals plc, shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ratio came in at 24.01.

The stock last ended the trading session at $136.56 and registered a market cap of $8.27B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) PEG ratio is at 0.75.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 14 times, 1 visits today)